text: <unk>  is a Ophthalmologic Agent that is FDA approved for the treatment of neovascular (wet) age-related macular degeneration.   Common adverse reactions include anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased intraocular pressure (IOP), ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbance, vitreous floaters, and vitreous opacities..
option_0: Pegaptanib
option_1: Toceranib
option_2: Semaxanib
option_3: Pazopanib hydrochloride
option_4: Cediranib
option_5: Alectinib
option_6: Gilteritinib
option_7: Regorafenib